Company Overview and News
Denbury Resources (DNR - Free Report) closed the most recent trading day at $5.27, moving -1.22% from the previous trading session. This change lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow gained 0.26%, while the tech-heavy Nasdaq lost 0.48%.
DNR BLT BHP BCBP BHPBF SDPI BBL BHP SPDI BHPLF
Larger and more financially healthy E&P companies are grouped together for analysis purposes in this "Tier One Producer" or "TOP Club"
CRC GDPMQ CHKVP PSX CRK QEP CHKVZ CRZO GDAOQ EGC EXXIQ SNZYP GDRRQ AMPY TALO SRCI EEXXQ BCEI RRS JONE WPX ESTE EXXI GDP CHK SGY TTEN MPOYQ SDRXP LINE SDRXQ APA HES DVN PVA EPE PIONF CHKDH CHKDG MCF CHKDJ ROSEU VNR CHKDP REI RSPP JNEEP AMR AMGP JAG ROSE LINEQ CKRGZ EVEP EOG RGRYY UPLMQ VNRCP PIO LNGG AR SWTF AM EXIXQ CHAP VNRBP SN XOG NBL WLL PDCE SM CTLR HKRCP SD RGRLF RRC DNR MPO VNRAP CLR GDPAN GDPAQ ECR CHPE UPL WPXP SDRPQ REN PE CXO RRL SCAZP AXAS COP AREX ECA SFY EVEPQ CDEV BRMR GDPM PVAYQ VNRR ECA SBOW CHKWZ GDUEQ SDOCQ GDANQ CHK.WI PVAC LPI WES HK HPR BRY
Denbury Resources (DNR - Free Report) closed the most recent trading day at $5.74, moving +1.95% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.42%. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
DNR XOM LGNZZ LGNYZ LGND LGNXZ LGNDZ
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Denbury Resources (DNR - Free Report) . This company, which is in the Zacks Oil and Gas - Exploration and Production - United States industry, shows potential for another earnings beat.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Earnings estimates for Targa Resources, Inc. (TRGP - Free Report) have been revised upward over the past 60 days, reflecting analyst’s confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 675% and 20.9% north to 27 cents and 52 cents per share, respectively. Also, the Zacks Consensus Estimate for current-year earnings per share reflects a significant year-over-year surge of 162.
TCP NGLS DNR NOG TRGP YY
WPX Energy’s (WPX - Free Report) earnings estimates have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has also moved up 33.3% and 8.1%, respectively, to 20 cents and 80 cents per share, over the same time frame. WPX Energy, currently a Zacks Rank #3 (Hold) stock, engages in the production of oil, natural gas and natural gas liquids.
DNR WPXP NOG EGN WPX YY
Investors in Denbury Resources Inc. (DNR - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 21, 2018 $6.00 Call had some of the highest implied volatility of all equity options today.
DNR WBA LMAT YY
Earnings estimates for Unit Corporation (UNT - Free Report) have been revised upward over the past 60 days, reflecting analyst’s confidence in the stock. The Zacks Consensus Estimate for 2018 and 2019 earnings has moved 14.7% and 25.3% north to 86 cents and $1.09 per share, respectively. Also, the Zacks Consensus Estimate for current-year earnings per share reflects a significant year-over-year surge of 59.
LMT TCP DNR WPXP UNT UTX WPX
For those looking to find strong Oils-Energy stocks, it is prudent to search for companies in the group that are outperforming their peers. Denbury Resources (DNR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of DNR and the rest of the Oils-Energy group's stocks.
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive,” and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
ONDK DNR CFCO CFCOW CFCOU
Chicago, IL – October 1, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include CNX Resources Corp. (CNX - Free Report) , Apache Corp. (APA - Free Report) , Northern Oil and Gas, Inc. (NOG - Free Report) and Denbury Resources Inc.
EA APA DNR CNX.WI NOG FSLR
The U.S. energy sector has been burgeoning lately. With rising oil prices and consistent efforts by the government to keep production high, gains for the space have been abundant. Experts are of the view that China’s tariffs on its natural gas imports from America will end up harming the world’s second largest economy more.
APA DNR CNX.WI NOG GPN
2018-09-27 zacks - 1
Noble Energy Inc. (NBL - Free Report) announced that it has executed multiple agreements to support the delivery of natural gas from the Leviathan and Tamar fields, offshore Israel, into Egypt. The company expects to commence operation of the Leviathan field by 2019-end and anticipates to sell a minimum of gross 350 million cubic feet of natural gas per day to contracted customers in Egypt. Also, Noble Energy is all set to invest approximately $200 million in Eastern Mediterranean Gas Company S.
NBL DNR CWEI NOG VNOM ROSE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to DNR / Denbury Resources Inc. on message board site Silicon Investor.
|DNR: Denbury Resources, Inc.||DNR: Denbury Resources, Inc.||DNR: Denbury Resources, Inc.||DNRE||DNRE||DNRE|
|MODERN RECORDS INC. (MZR.V u0026 MDNR.OTC)||MODERN RECORDS INC. (MZR.V u0026 MDNR.OTC)||MODERN RECORDS INC. (MZR.V u0026 MDNR.OTC)|
as of ET